Welcome to Greg Rowland’s Alzheimer’s Research Report, delivering clear, evidence-based breakdowns of emerging therapies and diagnostic breakthroughs.
Free Subscribers: Access the high-level executive summary below.
Paid Subscribers: Unlock the full analysis, deep dives into clinical trials, and data-backed takeaways.
Select an option below to support independent research and unlock full access:
Monthly Pass: $10/month — Full access to all current and archived reports.
Annual Pass: $100/year — Save $20 and secure uninterrupted insights.
Founder’s Circle: $250/year — Includes full access plus an exclusive monthly
SUMMARY
Focused ultrasound technology is emerging as a promising, noninvasive breakthrough to enhance brain treatments by opening the blood-brain barrier (BBB) to deliver therapeutics directly to targeted areas.
The Problem: The blood-brain barrier protects the brain, but it also blocks over 98% of therapeutic drugs from reaching central nervous system (CNS) targets, creating a major obstacle for treating diseases like Alzheimer’s, Parkinson’s, ALS, and glioblastoma.
The Breakthrough: Neumous, a clinical-stage medical device company founded in 2022 by Dr. Juyoung “Jay” Park, has developed a noninvasive platform that uses concentrated acoustic energy to safely and temporarily loosen BBB tight junctions for targeted drug delivery.
Key Innovation: Unlike traditional systems that rely on expensive and complex MRI guidance, Neumous uses neuronavigation-guided targeting. This MRI-free approach drastically improves accessibility and lowers costs for clinical settings.
Current Progress: Early-stage clinical trials evaluating standalone safety and feasibility are underway, with initial Alzheimer’s patients already treated. Preliminary data confirms safety and technical viability, while expansion plans into the U.S. market remain under development.
